Chengdu Kanghua Biological Products

SHE:300841 China Biotechnology
Market Cap
$1.08 Billion
CN¥7.90 Billion CNY
Market Cap Rank
#7586 Global
#1318 in China
Share Price
CN¥60.83
Change (1 day)
+0.53%
52-Week Range
CN¥50.34 - CN¥92.06
All Time High
CN¥399.08
About

Chengdu Kanghua Biological Products Co., Ltd. engages in the research, development, production, sale, and technical service of biological products in China. It offers group ACYW135 meningococcal polysaccharide vaccines; and freeze-dried human diploid cell rabies vaccines. The company also develops seasonal influenza vaccines. In addition, it exports its products. Chengdu Kanghua Biological Produc… Read more

Chengdu Kanghua Biological Products - Asset Resilience Ratio

Latest as of March 2024: 1.19%

Chengdu Kanghua Biological Products (300841) has an Asset Resilience Ratio of 1.19% as of March 2024. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.

Liquid Assets
CN¥50.00 Million
Cash + Short-term Investments
Total Assets
CN¥4.20 Billion
All company assets
Resilience Assessment
Low
Financial Resilience Level

Asset Resilience Ratio Trend (2020–2020)

This chart shows how Chengdu Kanghua Biological Products's Asset Resilience Ratio has changed over time. Compare with other companies' asset resilience ratios.

Liquid Assets Composition Over Time

This chart breaks down Chengdu Kanghua Biological Products's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time.

Current Liquid Assets Breakdown

Component Amount % of Total Assets
Cash & Equivalents CN¥0.00 0%
Short-term Investments CN¥50.00 Million 1.19%
Total Liquid Assets CN¥50.00 Million 1.19%

Asset Resilience Insights

  • Limited Liquidity: Chengdu Kanghua Biological Products maintains only 1.19% of assets in liquid form.
  • This low level may indicate efficient asset utilization but could pose risks during economic downturns.
  • The company has significant short-term investments, indicating active treasury management.

Chengdu Kanghua Biological Products Industry Peers by Asset Resilience Ratio

Compare Chengdu Kanghua Biological Products's asset resilience ratio with other companies in the same industry.

Company Industry Asset Resilience Ratio
Halozyme Therapeutics Inc
NASDAQ:HALO
Biotechnology 12.71%
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
Biotechnology 3.28%
ESSA Pharma Inc
NASDAQ:EPIX
Biotechnology 21.42%
Shenzhen CAU Technology Co Ltd
SHE:000004
Biotechnology 6.20%
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403
Biotechnology 6.88%
Nanhua Bio Medicine Co Ltd
SHE:000504
Biotechnology 11.93%
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518
Biotechnology 0.03%
Chengzhi Shareholding Co Ltd
SHE:000990
Biotechnology 6.73%

Annual Asset Resilience Ratio for Chengdu Kanghua Biological Products (2020–2020)

The table below shows the annual Asset Resilience Ratio data for Chengdu Kanghua Biological Products.

Year Asset Resilience Ratio (%) Liquid Assets Total Assets Change
2020-12-31 8.38% CN¥180.00 Million CN¥2.15 Billion --
pp = percentage points